Department of Medical Oncology, Dokuz Eylül University Institute of Oncology, IZMIR, TURKEY.
Turk Patoloji Derg. 2023;39(1):55-63. doi: 10.5146/tjpath.2022.01588.
There is not enough data in the literature regarding Her-2 overexpression in uterine carcinosarcomas or its association with the prognosis. The aim of this study was to determine the Her-2 overexpression rate in uterine carcinosarcoma and to evaluate its relationship with the prognosis.
Her-2 protein and gene status were evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively, in hysterectomy specimens from 51 patients with uterine carcinosarcoma.
Her-2 protein expression in the epithelial component was negative in 42 patients (score 0 in 33 cases, score (+1) in 9 cases), score (+2) in 7 patients and score (+3) in 2 patients. None of the patients had Her-2 protein expression within the sarcomatous component of the tumors. Her-2 gene was not amplified in epithelial or mesenchymal tumor areas according to the FISH method. There was no difference between the Her-2 overexpression negative and positive groups in terms of disease-free survival (DFS) and overall survival (OS). Her-2 overexpression was significantly higher in tumors of patients diagnosed at 65 years or older (p=0.046).
In our study, no relationship could be shown between Her-2 overexpression and prognosis in uterine carcinosarcoma. More comprehensive studies are needed to illustrate the relationship between Her-2 overexpression and carcinosarcoma prognosis.
关于子宫癌肉瘤中 Her-2 过表达及其与预后的关系,文献中数据不足。本研究旨在确定子宫癌肉瘤中 Her-2 过表达率,并评估其与预后的关系。
对 51 例子宫癌肉瘤患者的子宫切除术标本分别采用免疫组织化学(IHC)和荧光原位杂交(FISH)检测 Her-2 蛋白和基因状态。
42 例患者的上皮成分中 Her-2 蛋白表达阴性(33 例评分为 0,9 例评分为(+1),7 例评分为(+2),2 例评分为(+3))。肿瘤的肉瘤成分中均未见 Her-2 蛋白表达。根据 FISH 方法,上皮或间叶肿瘤区域均未扩增 Her-2 基因。在无病生存(DFS)和总生存(OS)方面,Her-2 过表达阴性和阳性组之间无差异。在诊断年龄为 65 岁或以上的患者中,Her-2 过表达显著更高(p=0.046)。
在本研究中,未显示 Her-2 过表达与子宫癌肉瘤的预后之间存在关系。需要更全面的研究来阐明 Her-2 过表达与癌肉瘤预后之间的关系。